Latest News & Features
Big Pharma
Being both an innovator and a generic drug company gives Teva a good view of the patent litigation landscape, as Galit Gonen, general counsel, Teva Europe, tells LSIPR. 27 October 2015
Asia
As well as much other debate, the High Court’s decision in D’Arcy v Myriad Genetics has created uncertainty in terms of the patent eligibility of naturally occurring molecules other than DNA, says Tania Obranovich, special counsel at Watermark Intellectual Asset Management. 22 October 2015
Biotechnology
The life sciences sector in the UK is booming, as delegates at October’s BIA forum heard. Jane Wainwright of Potter Clarkson reports. 22 October 2015
Biotechnology
The Dutch lobby to amend Directive 98/44/EC on the legal protection of biotechnological inventions will severely damage the ability of the biotech sector to innovate—and for no tangible reason, says Annemiek Verkamman of HollandBIO. 15 October 2015
Asia
The High Court of Australia’s decision in Myriad has led some observers to hit the panic button and demand immediate legislative change, but only isolated naturally-occurring genes are affected and the ruling should be read in that light, says Grant Shoebridge of Shelston IP. 15 October 2015
Big Pharma
The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford. 8 October 2015
Biotechnology
Supplementary protection certificates should take effect once an applicant for marketing authorisation has been notified of the authorisation, an advocate-general has urged the Court of Justice of the European Union to confirm. 2 October 2015
Big Pharma
The Court of Justice of the European Union has clarified when pharmaceutical patent owners may rely on the Specific Mechanism to prevent parallel imports of their products. 2 October 2015
Big Pharma
An Advocate General in the Court of Justice of the European Union, Niilo Jääskinen, has clarified how the regulation for supplementary protection certificates should be interpreted concerning medicinal products made with a combination of active ingredients. 2 October 2015
Big Pharma
The CJEU’s decision in Forsgren has brought greater clarity to the scope of the SPC regulation, including whether a substance is an active ingredient, as Avi Toltzis and Penny Gilbert of Powell Gilbert explain. 1 October 2015